ProQR Therapeutics (PRQR) Accounts Payables (2013 - 2026)

ProQR Therapeutics has reported Accounts Payables for 14 years, with the latest figure at $221270.9 in Q1 2026.

• Quarterly Accounts Payables fell 49.19% year-over-year to $221270.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221270.9 (down 49.19% YoY) and the FY2025 annual result came in at $346885.0, up 1928.86% from the prior year.
• Accounts Payables declined to $221270.9 in Q1 2026 per PRQR's latest filing, from $346885.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $1.7 million in Q4 2023 and troughed at $17097.5 in Q4 2024.
• A 5-year average of $473039.6 and a median of $356561.8 in 2025 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 278695.49% in 2022, then plunged 98.97% in 2024.
• Over 5 years, Accounts Payables stood at $399937.0 in 2022, then jumped by 314.57% to $1.7 million in 2023, then slumped by 98.97% to $17097.5 in 2024, then jumped by 1928.86% to $346885.0 in 2025, then sank by 36.21% to $221270.9 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $221270.9, $346885.0, and $356561.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.